Login / Signup

Prognostic utility of triglyceride-rich lipoprotein-related markers in patients with coronary artery disease.

Ye-Xuan CaoHui-Wen ZhangJing-Lu JinHui-Hui LiuYan ZhangRui-Xia XuYing GaoYuan-Lin GuoCheng-Gang ZhuQi HuaYan-Fang LiRaul D SantosNa-Qiong WuJian-Jun Li
Published in: Journal of lipid research (2020)
TG-rich lipoprotein (TRL)-related biomarkers, including TRL-cholesterol (TRL-C), remnant-like lipoprotein particle-cholesterol (RLP-C), and apoC-III have been associated with atherosclerosis. However, their prognostic values have not been fully determined, especially in patients with previous CAD. This study aimed to examine the associations of TRL-C, RLP-C, and apoC-III with incident cardiovascular events (CVEs) in the setting of secondary prevention of CAD. Plasma TRL-C, RLP-C, and total apoC-III were directly measured. A total of 4,355 participants with angiographically confirmed CAD were followed up for the occurrence of CVEs. During a median follow-up period of 5.1 years (interquartile range: 3.9-6.4 years), 543 (12.5%) events occurred. Patients with incident CVEs had significantly higher levels of TRL-C, RLP-C, and apoC-III than those without events. Multivariable Cox analysis indicated that a log unit increase in TRL-C, RLP-C, and apoC-III increased the risk of CVEs by 49% (95% CI: 1.16-1.93), 21% (95% CI: 1.09-1.35), and 40% (95% CI: 1.11-1.77), respectively. High TRL-C, RLP-C, and apoC-III were also independent predictors of CVEs in individuals with LDL-C levels ≤1.8 mmol/l (n = 1,068). The addition of RLP-C level to a prediction model resulted in a significant increase in discrimination, and all three TRL biomarkers improved risk reclassification. Thus, TRL-C, RLP-C, and apoC-III levels were independently associated with incident CVEs in Chinese CAD patients undergoing statin therapy.
Keyphrases
  • coronary artery disease
  • low density lipoprotein
  • cardiovascular disease
  • cardiovascular events
  • patients undergoing
  • stem cells
  • risk assessment
  • type diabetes
  • mesenchymal stem cells
  • replacement therapy